INOVIQ

Investor Presentation

ASX: IIQ | 9 August 2022

Disclaimer

This presentation has been prepared by INOVIQ Limited ("INOVIQ" or the "Company") based on information available to it as at the date of this presentation. This presentation contains general and background information about the Company's activities current as at the date of the presentation and should not be considered to be comprehensive or to comprise all the information that an investor should consider when making an investment decision and does not contain all information about the Company's assets and liabilities, financial position and performance, profits and losses, prospects, and the rights and liabilities attaching to the Company's securities necessary to make an investment decision. The information in this presentation should be read in conjunction with the Company's other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange (ASX), available at www.asx.com.au. The information in this presentation is based on the Company's own information and estimates and has not been independently verified. The Company is not responsible for providing updated information and assumes no responsibility to do so. Any investment in the Company should be considered speculative and there is no guarantee that they will make a return on capital invested, that dividends would be paid, or that there will be an increase in the value of the investment in the future.

This Presentation may contain certain "forward-looking statements" that are based on management's beliefs, assumptions and expectations and on information currently available to management. The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Any indications of, and guidance on, future operating performance, earnings, financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions.

Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including INOVIQ or any of its advisers). In particular, no representation, warranty or assurance (express or implied) is given that the occurrence of the events expressed or implied in any forward-looking statements in this Presentation will actually occur. Actual operations, results, performance, targets or achievement may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based.

Nothing contained in this Presentation constitutes investment, legal, tax or other advice. This Presentation does not purport to be all inclusive or to contain all information which its recipients may require in order to make an informed assessment of the Company's prospects.

You should note that any past performance is given for illustrative purposes only and should not be relied on as (and is not) an indication of the Company's views on its future financial performance or condition. Past performance, including past share price performance, of INOVIQ cannot be relied on as an indicator of (and provides no guidance as to) future performance including future share price performance.

Vision

Our vision is to enable **earlier and more accurate** detection of cancer and other diseases to improve treatment options, **patient outcomes and survival**

Company overview

INOVIQ Ltd

- Developing diagnostic and exosome-based solutions for cancer and other diseases
- Proprietary technology platforms for biomarker isolation and detection
- Products in-market for exosome research & bladder cancer
- Multi-product pipeline for detection and monitoring of breast, ovarian and other cancers targeting US$15b global markets
- Compelling early data in breast and ovarian cancers
- Multiple key inflection points over next 12 months
- Strong cash position of $15.4m to fund operations and pipeline development

Financial information (ASX:IIQ)	
Ordinary shares	92,018,702
Share price (5/8/22)	A$0.63
Market capitalisation	A$57.97m
Cash position (30/6/22)	A$15.4m
Ave monthly cash burn (Q4 FY22)	A$561k
Top 20 Shareholders (5/8/22)	34.6%

Share price performance

Unmet need for earlier cancer detection

Problem

- Cancers are often diagnosed at late-stage after symptoms have appeared, resulting in poor prognosis
- Detection of early-stage cancers often limited by high false-positives &/or poor sensitivity
- Current tests can have safety, cost and convenience issues reducing test participation rates

Unmet need

- Unmet need for non-invasive, accurate and reliable diagnostic tests for earlier cancer detection
- Earlier detection improves treatment options, patient outcomes & survival [1]



1 SEER 18 2010-2016

Global cancer diagnostics market

Global cancer burden is 50.6m survivors, **19.3m new cases and 10.0m deaths pa**[1]

Global cancer diagnostics market valued at **US$250b**[2]

INOVIQ is targeting markets worth over US$15b for some of the **world's most common and deadliest cancers**



GLOBAL CANCER DIAGNOSTIC SALES BY SEGMENT ($US)

1. GLOBOCAN (IARC) 2020; 2. Grand View Research 2019. https://www.grandviewresearch.com/press-release/global-cancer-diagnostics-market

Our technology platforms

INOVIQ has patented technologies and products in-market

SubB2M	NETs	BARD1	HTERT
Highly specific probe that detects the pan-cancer marker Neu5Gc found in multiple human cancers.	**NETs platform enables the capture of target analytes from any biofluid.**	**Biomarker technology covering various BARD1 tumour markers and methods of use for diagnostic applications.**	**Anti-hTERT antibody technology that detects hTERT that is upregulated in various human cancers.[1]**
Applications for **pan-cancer detection and monitoring** to improve performance of existing cancer biomarker tests.	Initial applications enabling **exosome isolation, biomarker discovery and diagnostics**.	Applications for **earlier cancer detection**.	Applications in **immunocytochemistry** (ICC).
Feasibility data showing a SubB2M-based SPR test detects breast and ovarian cancers across all stages with over 95% sensitivity and 100% specificity.	EXO-NET® research tools available in-market to capture exosomes with speed, purity and yield advantages.	Feasibility data showing high accuracy of BARD1 autoantibody tests to detect ovarian, breast and lung cancers.	hTERT ICC test available in-market as an adjunct to urine cytology to assist the diagnosis of bladder cancer.

1. *hTERT is a component of telomerase*

Q4 FY22
quarterly highlights

INOVIQ

SubB2M | Improving the accuracy of existing standard of care tests

- Master Manufacturing Agreement executed with cGMP and ISO-certified, MP Biomedicals for production of the SubB2M protein for SubB2M-based tests [2]
- ResearchDx, a US-based contract diagnostics organisation, engaged to further develop and validate SubB2M-based tests [1]
- Data package for SubB2M/CA15.3 and SubB2M/CA125 immunoassays, SubB2M and antibodies were transferred to ResearchDx for commercial assay development [1]
- SubB2M-CA15.3 assay for detection of breast cancer assay successfully replicated by ResearchDx, now undergoing optimisation and validation [3]
- SubB2M/CA15.3 assay development on-track to commence clinical testing in 4Q CY22



FIGURE: ResearchDx data shows SubB2M-CA15.3 assay measures from 5 - 250 U/ml. Limit of Quantitation 5 U/ml and CV 7.8%.

CDO = Contract Diagnostics Organisation; 1. ResearchDx engaged under Master Services Agreement (ASX: 5/4/22); 2. INOVIQ signs key manufacturing agreement to advance its SubB2M-based tests (2 May 2022); 3. SubB2M US patent grant and program update (ASX: 1/7/22)

SubB2M | Papers and patents

- SubB2M paper published in high impact journal, BMC Cancer [1]
- SubB2M was used to show that Neu5Gc serum biomarker levels can discriminate breast cancer patients from cancer-free individuals with 99% sensitivity and 100% specificity, in the samples tested
- AU Patent No 2017358401 granted covering the SubB2M technology. First patent granted covering the SubB2M technology. Due to expire 9/11/2037 [2]
- US patent No 11,371,033 granted covering the SubB2M technology. Second patent granted for the technology. Expires 9/7/2038 [3]

Researchers conclude "Neu5Gc serum biomarkers are a promising new tool for disease monitoring for breast cancer that may complement current imaging-and biopsy-based approaches."

Excerpt from the *"N-glycolylneuraminic acid serum biomarker levels are elevated in breast cancer patients at all stages of disease"*, paper in *BMC Cancer* journal


BMC Cancer

RESEARCH ARTICLE Open Access

N-glycolylneuraminic acid serum biomarker levels are elevated in breast cancer patients at all stages of disease

1. SubB2M paper published in BMC Cancer Journal (ASX: 6/4/22); 2. Australian patent granted for SubB2M technology (ASX: 3/5/22); 3. SubB2M US patent and program update (ASX: 1/7/22)

SubB2M | Melanoma IHC data

- Immunohistochemistry (IHC) feasibility study successfully completed using INOVIQ's SubB2M probe to aid in diagnosis of malignant melanoma in tissue samples [1]
- Data from 144 tissue samples in this feasibility study demonstrated that SubB2M IHC detected melanoma with 91% sensitivity and discriminated between malignant melanoma and benign skin lesions
- SubB2M-based IHC applications represent a new product opportunity for SubB2M as an IHC reagent in the $1.9b IHC market
- INOVIQ to seek partners to sublicence the further development and commercialisation of SubB2M IHC tissue-based tests



FIGURE: SubB2M IHC detection with UV Red Detection Kit on Roche Ventana Bench Mark

1.. Positive SubB2M IHC results for melanoma (ASX: 26/7/22)

EXO-NET I Exosome isolation tools

- **EXO-NET pan-exosome capture** is a 'research use only' (RUO) product for isolation of exosomes from body fluids (plasma, urine and saliva) with speed, purity and yield advantages
- Enables **rapid, efficient and scalable isolation** of enriched exosomes
- **Commercialisation** strategy to embed EXO-NET into the discovery, research & development phases of future exosome-based diagnostics & therapeutics
- Expanding **EXO-NET pipeline** for isolation of specific exosome subsets for use in target disease indications
- Building **collaborations with KOLs** to validate EXO-NET use across cancer, inflammatory, metabolic and neurodegenerative disease applications
- Transferring EXO-NET **manufacturing** to Melbourne to automate production under GMP conditions

EXO-NET I Exosome-based diagnostics pipeline

Collaboration with UQ to develop world-first exosome-based ovarian cancer screening test[1]

- UQ to develop **exosome-based blood test for the earlier detection of ovarian cancer** under a $2.7m MRFF[2] grant
- INOVIQ to provide its **EXO-NET technology** for fast, accurate and scalable exosome isolation in thousands of blood samples
- INOVIQ has the **exclusive option to license** rights to the development and commercialisation of UQ's exosome-based early detection test for ovarian cancer to improve women's health outcomes and help save lives
- The OCRF-7 exosomal protein and miRNA biomarkers were validated in an retrospective case-control study achieving over **90% accuracy** for detection of stage I / II ovarian cancer[3]



FIGURE: Retrospective case (n = 153) : control (n= 312) study comparing accuracy of OCRF-7 algorithm to CA-125 assay

1. The University of Queensland (UQ) (ASX: 1/4/22); 2. Medical Research Future Fund (MRFF);
3. Research supported by a grant from the Ovarian Cancer Research Foundation (OCRF)

EXO-NET I Commercial progress

INOVIQ engages US-based contract sales team to accelerate EXO-NET roll out[1]

- INOVIQ engages US-based Percorso Life Sciences to provide contract sales force and logistics services to accelerate commercial roll-out of EXO-NET® products in the USA
- Contract sales force covers the key East-Coast, West-Coast and Mid-West US regions
- Services include marketing, sales, inventory, logistics and warehousing of EXO-NET research tools to academia and biopharma customers
- Engagement aligned with INOVIQ's strategy to first commercialise EXO-NET as a research tool in the global exosome research market, which is expected to reach US$661 million by 2026, with US representing 41.5% of market

"We believe that EXO-NET is an important technology that will provide US researchers with a much-needed tool to take the next steps to advance their exosome research."

Bryan Rittenberry, Chief Business Officer and Partner at Percorso

GLOBAL MARKET OPPORTUNITY FOR EXOSOME RESEARCH MARKET

US$661 million

1. INOVIQ engages US-based contract sales team to accelerate EXO-NET roll out (ASX: 21/7/22)

EXO-NET | Papers and patents

- Scientific Statement, co-authored by INOVIQ's Chief Scientific Officer, Professor Greg Rice, published by the Endocrine Society [1]
- The Statement outlines the emerging role of extracellular vesicles (EVs) in the field of endocrinology and the potential application of EVs as biomarkers for disease
- INOVIQ and University of Sydney present new EXO-NET data at International Society for Extracellular Vesicles (ISEV) Annual Meeting held in Lyon, France [2]
- The research establishes the utility for INOVIQ's EXO-NET EV isolation tool for on-bead FTIR analysis, thereby offering a simple, fast, and effective method for classifying cancer cells in a patient



Extracellular Vesicles and Their Emerging Roles as Cellular Messengers in Endocrinology: An Endocrine Society Scientific Statement

1. INOVIQ CSO co-authors scientific statement on exosomes (ASX: 26/4/22); 2. INOVIQ and University of Sydney present new EXO-NET data at ISEV (ASX: 27/05/22)

Strategy & Growth Plans

Products and pipeline

PRODUCT	INDICATION	PLATFORM	USE	RESEARCH	ASSAY DEVELOPMENT	CLINICAL DEVELOPMENT	REGISTRATION
hTERT[1]	Bladder Cancer	ICC	Adjunct to cytology				★ In-market
EXO-NET-RUO	Exosome Capture	Device	Research tool				★ In-market
Exosome-OC[2] **(OCRF-7)**	Ovarian Cancer	Multiomic	Screening				(TBA)
SubB2M-BCM	Breast Cancer	Immunoassay	Monitoring				2023
SubB2M-OCM	Ovarian Cancer	Immunoassay	Monitoring				2023
SubB2M-PCS	Prostate Cancer	Immunoassay	Detection				
SubB2M-PaC	Pancreatic Cancer	Immunoassay	Detection				
BARD1-Ovarian[3]	Ovarian Cancer	Immunoassay	Detection				
BARD1-Breast[3]	Breast Cancer	Immunoassay	Detection				
BARD1-Lung[3]	Lung Cancer	Immunoassay	Detection				

**RUO = Research Use Only; ICC = Immunocytochemistry;*
1. Adjunct to urine cytology to assist the detection of bladder cancer; 2 Umbrella Research & Option Agreement with UQ, 3. Progression subject to completion of review (ASX: 28/3/22)

INOVIQ's scalable commercialisation strategy

Well trodden LDT to IVD commercialisation path

Our strategy for commercialising diagnostics implements a risk-based LDT to IVD dual commercialisation path.

We commercialise first as LDTs to enable early revenues, before undertaking large-scale clinical trials to support IVD regulatory approval, wider clinical adoption and revenue growth.

We then plan to expand market registrations and applications (uses and indications) for our technologies and tests.



Achievements and catalysts

1Q 2022

- ✓ EXO-NET collaborations (UQ)
- ✓ SubB2M manufacturing agreement (MP Biomedicals)
- ✓ SubB2M publication (BMC Cancer)
- ✓ Scientific statement on exosomes (Endocrine Reviews)
- ✓ New patents granted for BARD1 & EXO-NET

2Q 2022

- ✓ SubB2M assay development (ResearchDx)
- ✓ SubB2M patent granted
- ✓ Expanded R&D and commercial teams
- - SubB2M feasibility results for breast cancer immunoassay
- ✓ SubB2M IHC data for cancer
- ✓ EXO-NET data presentation at ISEV 2022

3Q 2022

- - New EXO-NET collaborations
- - EXO-NET publication (product comparison)
- - Progress on UQ collaboration for exosome OC test

4Q 2022

- ✓ Secure LDT laboratory partner
- ✓ Appoint US sales force for EXO-NET
- - Commence SubB2M accuracy study BC
- - Commence SubB2M accuracy study OC
- - Commence SubB2M comparison study to CA15.3
- - Commence SubB2M comparison study to CA125
- - Progress development of new EXO-NET products

2023

- - SubB2M BC test results
- - SubB2M OC test results
- - SubB2M analytical validation (lab)
- - SubB2M clinical validation (lab)
- - Launch SubB2M BC test (LDT)
- - Launch SubB2M OC test (LDT)
- - Secure partnering agreements for EXO-NET
- - Progress results on exosome OC test

INOVIQ

Investment proposition

1 Innovative Company

Focused on diagnostic and exosome-based solutions to improve health outcomes in cancer and other diseases

2 Patented Technology

Proprietary biomarker isolation & detection technologies with multiple applications

3 Strong Pipeline

Multi-product pipeline for detection of common and/or deadly cancers

4 Compelling Results

Early data for SubB2M and exosome-based tests show high accuracy for early detection &/or monitoring of breast & ovarian cancers

5 Commercialised Products

Products in-market for exosome research and bladder cancer

6 Significant growth Potential

Targeting unmet needs for cancer diagnostics in US$15b global markets

7 Experienced Leadership

Track record in healthcare leadership, diagnostic development and commercialisation

8 Strong cash Position

Cash of $15.4m as of 30 Jun 22 to fund operations and pipeline development

INOVIQ

Contacts

INOVIQ Ltd

23 Normanby Road
Notting Hill VIC 3168
Australia

p. +61 3 9548 7586
e. info@inoviq.com
w. www.inoviq.com

Dr Leearne Hinch
Chief Executive Officer
e. lhinch@inoviq.com
m. +61 400 414 416



Appendices

Healthcare Experienced Board

DR GEOFF CUMMING PhD
Non-Executive Chairman

Healthcare and biotechnology director with extensive diagnostics industry experience.

Previously Managing Director Roche Diagnostic Systems (Oceania), MD/CEO Biosceptre International Ltd and MD/CEO of Anteo Diagnostics Ltd.

Currently NED AnteoTech Ltd.

MAX JOHNSTON
Non-Executive Director

Healthcare industry director and international business leader with extensive experience across medtech, pharmaceuticals, consumer healthcare and consumer goods.

Previously President and CEO of Johnson & Johnson Pacific, NED of PolyNovo Ltd and CannPal Animal Therapeutics Ltd, and Chairman of AusCann Ltd.

Currently NED of Medical Developments International Ltd & Tissue Repair Ltd, and interim CEO of PolyNovo Ltd.

PHILIP POWELL
Non-Executive Director

Healthcare industry director and chartered accountant with extensive investment banking experience specialising in capital raisings, IPOs, mergers and acquisitions and other transactions across pharma, food and agriculture.

Previously at OAMPS Ltd and Arthur Andersen, and NED at Polynovo Ltd and Medical Developments International Ltd.

Currently NED RMA Global Ltd.

Prof ALLAN CRIPPS AO PhD
Non-Executive Director

Distinguished academic, clinical scientist and health services leader, having made significant contributions in immunology, diagnostics and health services.

Previously Pro Vice Chancellor (Health) at Griffith University where he was responsible for the establishment of the Health Faculty including the School of Medicine.

Currently Professor Emeritus at Griffith University and NED of Neurotech International Ltd.

Management

DR LEEARNE HINCH

Chief Executive Officer

An experienced biotechnology executive and life sciences commercialisation consultant.

Previous senior executive and consulting roles in ASX-listed biotechnology, multi-national and private companies across diagnostics, devices, therapeutics and animal health including Mars, Virbac, Chemeq, CollTech & OBJ.

DR GREG RICE PhD

Chief Scientific Officer

An internationally recognised scientist with over 30 years' experience and a successful track record in oncology research, biomarker trials and diagnostics commercialisation.

Previous leadership roles in academia and industry including UQ, Baker Heart Inst., UoM, Monash & HealthLinx.

TONY DI PIETRO

CFO & Company Secretary

Extensive corporate accounting experience in Australia and the UK, and a Graduate Diploma of Applied Corporate Governance.

Previous senior roles in ASX-listed biotechnology companies including Acrux Ltd.

Dr ROCCO IANNELLO

Business Development and Licensing Director

A business development professional and research scientist with senior experience in IP commercialisation, business development and licensing across medical devices & pharmaceuticals.

Has strong Australian and international networks across government, academia, industry and venture capital.

Strong patent portfolio

- Broad patent portfolio protecting IIQ's core biomarker isolation and detection technologies and products
- IP owned or exclusively licensed
- 42 granted patents, 14 pending and 2 international (PCT) applications (at 22/7/22)
- Protection across key jurisdictions (including US, Europe, Asia & Australia)
- Registered trademarks for INOVIQ® and EXO-NET®

Patent Family	Title	Granted	Pending	Expiry
SubB2M				
PCT/AU2017/051230 (WO 2018/085888)	Subtilase cytotoxin B subunit mutant	AU, US	BR, CA, CN, EP, IN, JP, KR, US (cont)	2037
PCT/AU2022/050470	Methods of analysing a sample			2042
BARD1				
PCT/FR01/02731 (WO/2002/018536)	Truncated BARD1 protein, and its diagnostic and therapeutic uses	US		2024
PCT/IB2011/053635 (WO/2012/023112)	BARD1 isoforms in lung and colorectal cancer and use thereof	AU, BR, CA, CN, CN(div) EP, HK, IL, JP, JP(div), SG, US, US (cont)		2031
PCT/IB2011/054194 (WO/2012/038932)	Kits for detecting breast or ovarian cancer in a body fluid sample and use thereof	EP, US, US (cont)		2031
PCT/EP2014/073834 (WO/2015/067666)	Lung Cancer Diagnosis	AU, CN, IL, JP, SG, KR, US	CA, EP, HK	2034
EP14002398.7	Non-coding RNA as diagnostic marker and treatment target	US		2035
hTERT				
PCT/AU2015/050060 (WO2015/120523)	Method of resolving inconclusive cytology to detect cancer	AU, CN, EP, IL, JP, US, US(cont)		2035
PCT/AU2016/050764 (WO2017/027928)	Method of detecting cancer in morphologically normal cells	JP	US	2036
Molecular NETs				
PCT/US2010/058086 (WO2011/066449)	Devices for detection of analytes	CN, US(cont1), US(cont2), US(cont3)	US(cont5)	2030
PCT/US2013/049779 (WO2014/011673)	Molecular Nets	EP		2033
PCT/US2014/029823 (WO2014/153262)	Molecular nets on solid phases	AU, CN	CA	2034
PCT/AU2022/050428	Methods relating to tumour-derived extracellular vesicles			2042

cont = continuation; div = divisional